Czechia – Antineoplastic and immunomodulating agents – Dodávky léků – RITUXIMAB 2026
Opportunity Score
Confidence: 50%
Complexity: low
1 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation
AI Analysis Summary
This open tender by Revmatologický ústav (Prague) for the supply of rituximab medicinal products (L01FA01) over 36 months, divided into two lots: Lot 1 (RIXATHON, CZK 33,776,000) and Lot 2 (no title, CZK 3,684,000). Awarded purely on lowest price. Submission via electronic profile, language Czech. Deadline: 16 June 2026, 10:00 local time. No extracted procurement documents; only structured notice and XML analyzed.
Strengths
Documents available
Open procedure
Low complexity
Risks
Submission deadline in 1 days
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
- Open procedure
- Electronic submission required via Open portal
- Submission language: Czech
Award Criteria
Nejnižší nabídková cena
Nejnižší nabídková cena
| Criterion | Type |
|---|---|
Nejnižší nabídková cena Nejnižší nabídková cena | Price |
Buyer
Name
Revmatologický ústav
Location
Praha, CZE
Buyer profile
Identifier
00023728
Lots (2)
Supplies of antineoplastic immunomodulating agent RIXATHON (rituximab) for 36 months, non-EU-funded.
Supplies of rituximab medicinal products (same CPV) for 36 months, EU-funded.
Procurement Details
Publication
02 Jun 2026
Deadline
16 Jun 2026, 08:00
Procedure
open
Contract
supplies
Duration
36 MONTH
Language
CES
Publication #
380976-2026
Classification
Performance: Czech Republic
Documents (2)
Opportunity Score
Confidence: 50%
Complexity: low
1 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation